Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04880356

Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.

General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Inherited Disease 2-Hydroxyglutaricaciduria Adrenal Gland Diseases Adrenal Insufficiency Adrenoleukodystrophy Alexander Disease Basal Ganglia Diseases Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cysts Demyelinating Diseases Digestive System Diseases Disease Attributes Endocrine System Diseases Fahr's disease Genetic Diseases, Inborn Genetic Diseases, X-Linked Hepatolenticular Degeneration Hereditary Central Nervous System Demyelinating Diseases Heredodegenerative Disorders, Nervous System Intellectual Disability Leukodystrophy, Globoid Cell Leukodystrophy, Metachromatic Leukoencephalopathies Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipidoses Liver Diseases Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Metabolic Disease Metabolic Diseases Metabolism, Inborn Errors Metal Metabolism, Inborn Errors Methylmalonic acidemia with homocystinuria Movement Disorders Neoplasms Nervous System Diseases Neuro-Degenerative Disease Neurobehavioral Manifestations Neurodegenerative Diseases Neurologic Disorder Neurologic Manifestations Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pelizaeus-Merzbacher Disease Peroxisomal Disorders Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy Rare Diseases Sphingolipidoses Sulfatidosis Undiagnosed Disease Undiagnosed Diseases X-Linked Intellectual Disability Xanthomatosis Xanthomatosis, Cerebrotendinous

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Milano, 20133, Italy

Location status: Recruiting

Location contact

Elena Mauro, MD

CONTACT

[email protected]

+39022394 ext. 2388

Ettore Salsano, MD

CONTACT

About this study

The study provides a collection of retrospective data from adult patients with ultra-rare inherited neurological diseases followed at "Carlo Besta" Neurological Institute from 1st January 2004 until March 2021. Further, prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years. Normal clinical practice will be followed for collection of the prospective data. Follow-up assessment will be performed at least once a year to evaluate the disease course. Based on their clinical manifestations, patients will be assessed by using quantitative functional tests (clinimetric tests such as Timed Up and Go Test) and traditional ordinal scales (such as the scale for the assessment and rating of ataxia (SARA). Moreover, a varying of laboratory and instrumental tests (e.g., neuroimaging, neurophysiological investigations, etc.) will be used according to clinical practice in selected patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18 years
  • Subjects with ultra-rare inherited degenerative and metabolic neurological diseases
  • Subjects with undiagnosed neurological diseases (when supposed to be inherited)

Exclusion criteria

  • none

Treatment and study plan

Collection of data

Other

collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases

Primary outcomes

  1. Verbal (letter) fluency

    Time frame: 10 years

    Repeated Montreal Cognitive Assessment (MoCA) letter F fluency subtest

  2. Stance and gait performances [Time Frame: 10 years] Stance and gait performances

    Time frame: 10 years

    Repeated SARA (Scale for the Assessment and Rating Ataxia) stance subtask, ambulation index (AI) and Timed Up and Go (TUG) test

  3. Upper limb motor function

    Time frame: 10 years

    Repeated ONLS (Overall Neuropathy Limitation Scale) arm scale

  4. Swallowing function (dysphagia)

    Time frame: 10 years

    Repeated NP-C mDRS (Niemann-Pick type C modified disability rating scale) swallowing scale

  5. Speech function (dysarthria)

    Time frame: 10 years

    Repeated NP-C mDRS language scale

  6. Bladder function

    Time frame: 10 years

    Repeated AADS (Adult Adrenoleukodystrophy Disability Score) Bladder function scale

  7. Sleep

    Time frame: 10 years

    Repeated assessment of presence or absence of sleep disturbances

  8. Quality of life

    Time frame: 10 years

    Repeated EuroQol-5D-5L (EQ-5D-5L) questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Ettore Salsano, MD

CONTACT

[email protected]

+39022394 ext. 3001

Renato Mantegazza, MD

CONTACT

[email protected]

+39022394 ext. 2321

Sponsors and collaborators

Lead sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Other

Registry information

Official study title

Clinical, Instrumental and Laboratory Data Collection of Subjects with Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases

Important dates

Study start
2021
Primary completion
2031
Study completion
2031
First posted
May 10, 2021
Registry last updated
Nov 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.